AdvaMed jumps into India device regulation reform effort; Judge dismisses Stryker surgical tool lawsuit;

@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev

@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce

@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce

> AdvaMed and other medical device industry reps want India's parliament to make sure it ensures "sufficient dialogue" with stakeholders before it revises a proposed bill that would modernize how the sector is regulated in the country. Story

> A bill sponsored by Utah Republican Sen. Orrin Hatch that would repeal the medical device tax advanced to the Senate Finance Committee. Story

> Cardica ($CRDC) said it won the FDA's 510(k) clearance for a new surgical tool and related part designed for stapling of tissue during intestinal and other procedures. Item

> A federal judge dismissed a lawsuit alleging that a Stryker ($SYK) surgical tool caused the misalignment of her knee implant. Story (sub. req.)

> Newly-public medical device manufacturer LDR Holding ($LDRH) lost nearly $15 million in its fourth quarter and $27.8 million for all of 2013, both jumps over the previous year. Story

Biotech News

@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech

@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce

@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce

@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce

> Celgene gambles $50M on Abide and its R&D work on enzyme 'superfamily'. More

> Bayer plans to ratchet up its R&D spend and chase down some deals. Article

Pharma News

@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma

@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton

@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce

@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce

> GSK trims Witty's bonus in face of China probe. Story

> Endo loss widens, R&D chief departs amid regulatory struggles. Article

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.